Physician profile
Megan Louise Miller
NPI 1104364884
$155,535.95
in general payments reported to CMS, 2019-2025
16 companies · $89K in 2025
The $89K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $298 · 2022: $513 · 2023: $16K · 2024: $50K · 2025: $89K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $107K · Travel and Lodging: $41K · Food and Beverage: $4,399 · Consulting Fee: $2,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,412.50 |
| Travel and Lodging | $40,613.26 |
| Food and Beverage | $4,399.01 |
| Consulting Fee | $2,300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $125,915.83 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $28,076.44 | 2021-2025 | |
| Novo Nordisk INC | $562.64 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $239.98 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Genzyme Corporation | $186.78 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $182.23 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $125.00 | 2023 | Amvuttra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.23 | 2021 | |
| Pfizer INC. | $31.10 | 2023 | |
| Alexion Pharmaceuticals, INC. | $24.69 | 2022 | |
| Abbott Laboratories | $20.00 | 2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $17.98 | 2025 | Korlym |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.80 | 2022 | |
| Glaxosmithkline, LLC. | $17.63 | 2023 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.53 | 2025 | Caplyta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $13.09 | 2023 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.